Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992066 | 0.90 | ACAT2 (0.32) | ACAT2 | |
| SCHEMBL17992100 | 0.89 | MAPK10 (0.32) | RAB9ANPC1LMNAHTT | |
| SCHEMBL17992054 | 0.89 | LMNA (0.34) | LMNA | |
| SCHEMBL17757606 | 0.89 | ALDH1A1 (0.41) | KMT2ARAB9ANPC1LMNAHTT | |
| SCHEMBL14398518 | 0.89 | KMT2A (0.41) | ACAT2KMT2ARAB9ANPC1HTT | |
| SCHEMBL17757467 | 0.89 | KMT2A (0.41) | ACAT2KMT2ARAB9ANPC1HTT | |
| SCHEMBL17757653 | 0.89 | KMT2A (0.41) | ACAT2KMT2ARAB9ANPC1HTT | |
| SCHEMBL17992105 | 0.89 | KMT2A (0.33) | ACAT2KMT2ATSHR | |
| SCHEMBL17757634 | 0.87 | KMT2A (0.39) | ACAT2KMT2ARAB9ANPC1HTT | |
| SCHEMBL17757431 | 0.86 | SSTR3 (0.38) | ACAT2KMT2ARAB9ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN (DE) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | ACAT2 1509/4885KMT2A 4303/4885RAB9A 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.